Skip to main content

Update on late relapse of germ cell tumor: a clinical and molecular analysis.

Publication ,  Journal Article
George, DW; Foster, RS; Hromas, RA; Robertson, KA; Vance, GH; Ulbright, TM; Gobbett, TA; Heiber, DJ; Heerema, NA; Ramsey, HC; Thurston, VC ...
Published in: J Clin Oncol
January 1, 2003

PURPOSE: Analysis of patients with late relapse (LR) of germ cell tumor (GCT) with reports on clinical characteristics, outcomes, and molecular and cytogenetic features. PATIENTS AND METHODS: Eighty-three patients evaluated at Indiana University from 1993 through 2000 for relapse of GCT more than 2 years from initial therapy were reviewed. Available specimens were investigated for expression of the transcription regulator FoxD3 and apurinic/apyrimidinic endonuclease and the presence of chromosome 12 abnormalities. RESULTS: Median interval from initial presentation to LR was 85 months. Forty-three of 49 LR patients who underwent surgery were rendered disease free (NED), and 20 (46.5%) remain continuously NED. Thirty-two patients received chemotherapy, but only six (18.8%) obtained a complete remission. Five of these patients remain continuously NED after chemotherapy alone, including three who were chemotherapy naïve. Eighteen of these 32 patients were successfully rendered NED by postchemotherapy surgery, and 12 remain continuously NED. Two patients continue on observation with no treatment for their LR. Overall, 69 of the 81 treated patients (85.2%) ultimately achieved an NED state, and 38 (46.9%) remain continuously NED with median follow-up from LR therapy of 24.5 months (range, 1 to 83 months), whereas nine other patients are currently NED after therapy for subsequent relapses. Because of the small numbers of specimens tested, we were unable to draw any definitive conclusions from the molecular and cytogenetic analyses. CONCLUSION: GCT patients require lifetime follow-up. At the time of LR, surgical resection alone remains our preferred therapy.

Duke Scholars

Published In

J Clin Oncol

DOI

ISSN

0732-183X

Publication Date

January 1, 2003

Volume

21

Issue

1

Start / End Page

113 / 122

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Repressor Proteins
  • Recurrence
  • Oncology & Carcinogenesis
  • Multivariate Analysis
  • Middle Aged
  • Male
  • Logistic Models
  • Humans
  • Germinoma
 

Citation

APA
Chicago
ICMJE
MLA
NLM
George, D. W., Foster, R. S., Hromas, R. A., Robertson, K. A., Vance, G. H., Ulbright, T. M., … Einhorn, L. H. (2003). Update on late relapse of germ cell tumor: a clinical and molecular analysis. J Clin Oncol, 21(1), 113–122. https://doi.org/10.1200/JCO.2003.03.019
George, David W., Richard S. Foster, Robert A. Hromas, Kent A. Robertson, Gail H. Vance, Thomas M. Ulbright, Troy A. Gobbett, et al. “Update on late relapse of germ cell tumor: a clinical and molecular analysis.J Clin Oncol 21, no. 1 (January 1, 2003): 113–22. https://doi.org/10.1200/JCO.2003.03.019.
George DW, Foster RS, Hromas RA, Robertson KA, Vance GH, Ulbright TM, et al. Update on late relapse of germ cell tumor: a clinical and molecular analysis. J Clin Oncol. 2003 Jan 1;21(1):113–22.
George, David W., et al. “Update on late relapse of germ cell tumor: a clinical and molecular analysis.J Clin Oncol, vol. 21, no. 1, Jan. 2003, pp. 113–22. Pubmed, doi:10.1200/JCO.2003.03.019.
George DW, Foster RS, Hromas RA, Robertson KA, Vance GH, Ulbright TM, Gobbett TA, Heiber DJ, Heerema NA, Ramsey HC, Thurston VC, Jung S-H, Shen J, Finch DE, Kelley MR, Einhorn LH. Update on late relapse of germ cell tumor: a clinical and molecular analysis. J Clin Oncol. 2003 Jan 1;21(1):113–122.

Published In

J Clin Oncol

DOI

ISSN

0732-183X

Publication Date

January 1, 2003

Volume

21

Issue

1

Start / End Page

113 / 122

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Repressor Proteins
  • Recurrence
  • Oncology & Carcinogenesis
  • Multivariate Analysis
  • Middle Aged
  • Male
  • Logistic Models
  • Humans
  • Germinoma